uploads///Chart

Allergan’s Developments in September

By

Sep. 28 2018, Updated 12:45 p.m. ET

Allergan’s recent developments

Allergan (AGN) is a specialty pharmaceutical company focused on organic as well as inorganic growth methods. The chart below highlights several recent developments for Allergan.

Article continues below advertisement

September’s developments

On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21. Through these combined efforts, Eastwood joined the company in delivering a message that Alzheimer patients need to be informed about the disease and treatments. LearnAboutAlz.com, an educational website from Allergan, is a resource for information on the condition.

On September 19, Allergan announced its plans to build a medical aesthetics innovation center in China at an investment of over $14.7 million. The center is expected to open in early 2019.

On September 14, Allergan announced the acquisition of Bonti Inc. We’ll discuss the details of the acquisition later in this series.

On September 14, Allergan hosted Medical Aesthetics Analyst Day. Allergan presented an overview of the global medical aesthetics market, Allergan’s product portfolio and pipeline, and initiatives to drive future growth.

On September 14, Allergan announced the clinical results for higher doses of BOTOX Cosmetic (onabotulinumtoxinA) and comparison with BOTOX Cosmetic 20 unit dose in patients with moderate to severe glabellar lines at week 24.

On September 12, Allergan announced the launch of SpotLyte, which is the first launch from Project Moonwalker. Project Moonwalker is the Allergan-owned digital ventures unit.

On September 6, Allergan announced the launch of SkinMedica Lumivive System, a dual-acting product. This skincare product works as a shield from blue light during the day and works as a skin repair process at night.

The VanEck Vectors Biotech ETF (BBH) holds 5.5% in Allergan (AGN), 9.6% in Amgen (AMGN), 5.8% in Biogen (BIIB), and 5.8% in Celgene (CELG).

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.